You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 17, 2021

Practical Law Life Sciences Global Guide: Medicinal Product Regulation and Product Liability in Cambodia

Subscribe to Updates

The latest updates to Practical Law’s Life Sciences Global Guide feature contributions from Tilleke & Gibbins attorneys in the firm’s Phnom Penh office, who wrote “Medicinal Product Regulation and Product Liability in Cambodia.”

This overview form Practical Law covers a range of regulatory issues related to the marketing and selling of pharmaceutical products, including the following:

  • Regulatory overview, including relevant authorities, scope, definitions, and general procedures for pharmaceuticals, biologicals, and medical devices and health care IT
  • Pricing, government funding, and reimbursement: Structure of the Cambodian health care system, price regulation, and reimbursement
  • Clinical trials
  • Manufacturing and distribution
  • Marketing: Authorization for marketing medicinal products, parallel imports and cross-border trade in medicines
  • Restrictions on dealings with health care professionals
  • Selling restrictions
  • Advertising and promotion
  • Data privacy
  • Packaging, labeling, and tracking
  • Product safety, quality, and liability
  • Local establishment, representation, and residency requirements
  • Reform

The full Medicinal Product Regulation and Product Liability in Cambodia chapter can be accessed on the Practical Law website.

Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

April 19, 2021
Thailand has made significant changes to its statutory interest rate framework for the first time in almost a century. Since 1925, the statutory interest rate codified in Thailand’s Civil and Commercial Code (the CCC) has remained at 7.5% per year. But with Covid-19 having an unprecedented impact on the Thai economy, the Thai Government, via emergency decree, has reduced the statutory rate. While the decree is largely aimed at providing relief to hard-hit SMEs and individual debtors, the amendments have broader implications for doing business in Thailand. Main Changes The new interest rate revisions are contained within the Emergency Decree Amending the Civil and Commercial Code B.E. 2564 (2021) (the Emergency Decree), which was published in the Government Gazette on April 10, 2021 and came into effect on April 11, 2021. The Emergency Decree amends Sections 7 and 224 of the CCC, which stated the previous statutory interest rate of 7.5% per year. The Emergency Decree makes three major changes. The first involves a reduction of the statutory interest rate from 7.5% per year to 3% per year in Section 7. The new 3% annual rate is subject to review every three years by the Ministry of Finance. The interest rate is subject to further change later by a royal decree. The second change concerns money debts under Section 224 of the CCC. The previous version of Section 224 stated, among other things, that a money debt based on a default bears interest of 7.5% per year. Under the Emergency Decree, the new actual statutory default interest rate is the statutory interest rate stated in Section 7 with an additional rate of 2% per year. The result is a 5% annual statutory default interest rate. Since the statutory default interest rate is based in part on the Section 7
Read More